phosphocitrate

10/01/1986 - "In addition to its possible therapeutic value as an anti-calcifying and anti-atherogenic compound, phosphocitrate may prove useful as an experimental probe for studying the cellular basis of atherogenesis."
09/16/1985 - "The potential exists for phosphocitrate to have a therapeutic role in atherogenesis through modulating Ca2+ movements in arterial smooth muscle."
10/01/1986 - "Phosphocitrate, a phosphorylated polycarboxylic acid ameliorates two early events in atherogenesis. "

01/01/2017 - "Phosphocitrate (PC) inhibits osteoarthritis (OA) in Hartley guinea pigs. "
09/30/2015 - "It is believed that phosphocitrate (PC) exerts its disease-modifying effects on osteoarthritis (OA) by inhibiting the formation of crystals. "
01/01/2014 - "Expression of phosphocitrate-targeted genes in osteoarthritis menisci."
01/01/2013 - "Phosphocitrate (PC), a calcification inhibitor, inhibits the development of crystal-associated osteoarthritis (OA) in Hartley guinea pigs. "
01/01/2013 - "Phosphocitrate is potentially a disease-modifying drug for noncrystal-associated osteoarthritis."

08/01/2006 - "The present study was undertaken to examine the role of calcification in OA disease progression and to evaluate a formulation of phosphocitrate (PC) as a potential therapeutic agent. "
04/01/1998 - "Phosphocitrate (PC) is the only treatment known to significantly delay disease progression in MPA. "
11/01/1993 - "Phosphocitrate prevents disease progression in murine progressive ankylosis."
11/01/1993 - "Mice with progressive ankylosis, a spontaneous arthropathy, were treated with phosphocitrate (PC) in vivo to determine the effect of PC on disease progression. "

02/01/2018 - "Effects of a phosphocitrate analogue on osteophyte, subchondral bone advance, and bone marrow lesions in Hartley guinea pigs. "
02/01/2018 - "Effects of a phosphocitrate analogue on osteophyte, subchondral bone advance, and bone marrow lesions in Hartley guinea pigs."
02/01/2018 - "The objectives of this study were: 1) to examine osteophyte formation, subchondral bone advance, and bone marrow lesions (BMLs) in osteoarthritis (OA)-prone Hartley guinea pigs; and 2) to assess the disease-modifying activity of an orally administered phosphocitrate 'analogue', Carolinas Molecule-01 (CM-01). "

02/01/1989 - "The ability of phosphocitrate to prevent hydroxyapatite crystallization, together with its membrane protective effect against preformed crystals, would suggest that the compound might have a useful future role against crystal-induced arthropathies."
11/01/1993 - "Mice with progressive ankylosis, a spontaneous arthropathy, were treated with phosphocitrate (PC) in vivo to determine the effect of PC on disease progression. "